Anthony  D'Adamio net worth and biography

Anthony D'Adamio Biography and Net Worth

SVP of Bioventus

Tony D’Adamio is Senior Vice President and General Counsel of Bioventus. He has nearly 30 years of senior legal executive experience with diagnostic, health care data and clinical service companies. Tony is responsible for all general and corporate legal matters as well as the ethics and compliance functions at Bioventus.

Prior to joining the company, he served as General Counsel & Secretary of Siemens Medical Solutions and earlier was Deputy General Counsel & Secretary of Siemens Healthcare Diagnostics. He also spent five years as Senior Counsel within the Diagnostics Division of Bayer Healthcare, prior to the acquisition of this business by Siemens. Tony began his legal career at the law firm of Bond, Schoeneck & King before taking corporate legal positions with companies including Group Health Incorporated, Quest Diagnostics and Covance.

He received his Juris Doctor cum laude from Howard University School of Law and a Bachelor of Arts from the State University of New York at Binghamton.

What is Anthony D'Adamio's net worth?

The estimated net worth of Anthony D'Adamio is at least $1.07 million as of June 21st, 2024. Mr. D'Adamio owns 95,576 shares of Bioventus stock worth more than $1,074,274 as of November 17th. This net worth evaluation does not reflect any other investments that Mr. D'Adamio may own. Learn More about Anthony D'Adamio's net worth.

How do I contact Anthony D'Adamio?

The corporate mailing address for Mr. D'Adamio and other Bioventus executives is 4721 EMPEROR BOULEVARD SUITE 100, DURHAM NC, 27703. Bioventus can also be reached via phone at 919-474-6700 and via email at [email protected]. Learn More on Anthony D'Adamio's contact information.

Has Anthony D'Adamio been buying or selling shares of Bioventus?

Anthony D'Adamio has not been actively trading shares of Bioventus within the last three months. Most recently, Anthony D'adamio sold 5,904 shares of the business's stock in a transaction on Friday, June 21st. The shares were sold at an average price of $5.57, for a transaction totalling $32,885.28. Following the completion of the sale, the senior vice president now directly owns 95,576 shares of the company's stock, valued at $532,358.32. Learn More on Anthony D'Adamio's trading history.

Who are Bioventus' active insiders?

Bioventus' insider roster includes Anthony D'Adamio (SVP), Kenneth Reali (CEO), and Mark Singleton (Sr. VP). Learn More on Bioventus' active insiders.

Are insiders buying or selling shares of Bioventus?

In the last twelve months, Bioventus insiders bought shares 2 times. They purchased a total of 105,500 shares worth more than $902,025.00. In the last twelve months, insiders at the sold shares 8 times. They sold a total of 55,904 shares worth more than $311,026.34. The most recent insider tranaction occured on August, 19th when Director John A Bartholdson bought 25,500 shares worth more than $218,025.00. Insiders at Bioventus own 32.9% of the company. Learn More about insider trades at Bioventus.

Information on this page was last updated on 8/19/2024.

Anthony D'Adamio Insider Trading History at Bioventus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/21/2024Sell5,904$5.57$32,885.2895,576View SEC Filing Icon  
6/17/2024Sell11,308$5.84$66,038.7281,630View SEC Filing Icon  
4/11/2024Sell3,054$4.75$14,506.5058,242View SEC Filing Icon  
3/15/2024Sell3,125$5.46$17,062.5051,371View SEC Filing Icon  
3/15/2023Sell3,409$1.39$4,738.5145,610View SEC Filing Icon  
4/4/2022Sell16,016$11.19$179,219.04148,309View SEC Filing Icon  
2/14/2022Sell1,294$11.99$15,515.06View SEC Filing Icon  
See Full Table

Anthony D'Adamio Buying and Selling Activity at Bioventus

This chart shows Anthony D'adamio's buying and selling at Bioventus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bioventus Company Overview

Bioventus logo
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $11.24
Low: $10.96
High: $11.30

50 Day Range

MA: $11.97
Low: $10.23
High: $13.71

2 Week Range

Now: $11.24
Low: $3.64
High: $14.38

Volume

278,283 shs

Average Volume

491,268 shs

Market Capitalization

$912.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88